Silence Therapeutics plc SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINESCHEDULE 13G/ASilence Therapeutics plcSLNCF5d

   Silence Therapeutics plc 5.3% stake

   • Tetragon Financial Management LP holds 5.3% of shares
   • 9,878,565 shares beneficially owned
   • Includes 1,500,000 Shares issuable upon exercise of call options

   Tetragon Financial Management LP, filed by

2. ROUTINESCHEDULE 13GSilence Therapeutics plcSLNCF5d

   Silence Therapeutics plc

   • Tetragon Financial Management LP filed Schedule 13G on 2026-10-13.
   • Owns 9,708,153 shares (5.2% of class).
   • Includes 1,500,000 Shares underlying 500,000 ADSs.

   Tetragon Financial Management LP, filed by

3. NOTABLESCHEDULE 13D/ASilence Therapeutics plcSLNCFAug 13

   Ownership stake disclosure by Richard Ian Griffiths (amended)

   Richard Ian Griffiths, filed by

4. ROUTINESCHEDULE 13G/ASilence Therapeutics plcSLNCFAug 13

   Ownership stake disclosure by Invus Global Management, LLC (amended)

   Invus Global Management, LLC, filed by

5. ROUTINE4Silence Therapeutics plcSLNCFAug 13

   Richard Ian Griffiths, insider filing for SLNCF

   Richard Ian Griffiths, reporting

6. ROUTINE8-KSilence Therapeutics plcSLNCFAug 12

   Current report

7. ROUTINE424B5Silence Therapeutics plcSLNCFAug 12

   Securities offering

8. ROUTINES-3MEFSilence Therapeutics plcSLNCFAug 11

   S-3MEF filing

9. ROUTINE424B5Silence Therapeutics plcSLNCFAug 10

   Securities offering

10. ROUTINE8-KSilence Therapeutics plcSLNCFAug 10

    Current report

11. NOTABLE10-QSilence Therapeutics plcSLNCFAug 10

    Quarterly report

12. ROUTINE8-KSilence Therapeutics plcSLNCFAug 10

    Current report

13. ROUTINE8-K/ASilence Therapeutics plcSLNCFJul 16

    Current report (amended)

14. NOTABLESCHEDULE 13D/ASilence Therapeutics plcSLNCFJul 8

    Ownership stake disclosure by Richard Ian Griffiths (amended)

    Richard Ian Griffiths, filed by

15. ROUTINE4Silence Therapeutics plcSLNCFJul 7

    Richard Ian Griffiths, insider filing for SLNCF

    Richard Ian Griffiths, reporting

16. ROUTINE8-KSilence Therapeutics plcSLNCFJun 23

    Current report

17. ROUTINE8-KSilence Therapeutics plcSLNCFJun 16

    Current report

18. ROUTINE8-KSilence Therapeutics plcSLNCFJun 11

    Current report

19. ROUTINEEFFECTSilence Therapeutics plcSLNCFMay 28

    Registration declared effective

20. ROUTINE424B5Silence Therapeutics plcSLNCFMay 27

    Securities offering

21. ROUTINE8-KSilence Therapeutics plcSLNCFMay 18

    Current report

22. ROUTINES-3Silence Therapeutics plcSLNCFMay 18

    Securities offering

23. NOTABLE10-QSilence Therapeutics plcSLNCFMay 7

    Quarterly report

24. ROUTINE8-KSilence Therapeutics plcSLNCFMay 7

    Current report

25. ROUTINEARSSilence Therapeutics plcSLNCFApr 29

    Annual report to shareholders

26. ROUTINEDEF 14ASilence Therapeutics plcSLNCFApr 29

    Proxy statement

27. ROUTINES-8Silence Therapeutics plcSLNCFMar 5

    Employee stock plan registration

28. NOTABLE10-KSilence Therapeutics plcSLNCFMar 5

    Annual report

29. ROUTINE8-KSilence Therapeutics plcSLNCFMar 5

    Current report

30. ROUTINE4Silence Therapeutics plcSLNCFFeb 13

    Richard Ian Griffiths, insider filing for SLNCF

    Richard Ian Griffiths, reporting

31. ROUTINESCHEDULE 13G/ASilence Therapeutics plcSLNCFFeb 9

    Ownership stake disclosure by Lombard Odier Asset Management (USA) Corp (amended)

    Lombard Odier Asset Management (USA) Corp, filed by

32. ROUTINE4Silence Therapeutics plcSLNCFJan 6

    5 insider filings

    James Ede-Golightly, insider filing for SLNCF

    Show all 5

    • 4Insider filing for SLNCFJan 6
    • 4Insider filing for SLNCFJan 6
    • 4Insider filing for SLNCFJan 6
    • 4Insider filing for SLNCFJan 6
    • 4Insider filing for SLNCFJan 6

    James Ede-Golightly, reporting

33. ROUTINE4Silence Therapeutics plcSLNCFDec 22, 2025

    3 insider filings

    Iain Ross, insider filing for SLNCF

    Show all 3

    • 4Insider filing for SLNCFDec 22, 2025
    • 4Insider filing for SLNCFDec 22, 2025
    • 3New insider at SLNCFDec 22, 2025

    Iain Ross, reporting

34. ROUTINE8-K/ASilence Therapeutics plcSLNCFDec 22, 2025

    Current report (amended)

35. ROUTINE8-KSilence Therapeutics plcSLNCFDec 22, 2025

    Current report

36. ROUTINE8-KSilence Therapeutics plcSLNCFDec 15, 2025

    Current report

37. NOTABLE10-QSilence Therapeutics plcSLNCFNov 6, 2025

    Quarterly report

38. ROUTINE8-KSilence Therapeutics plcSLNCFNov 6, 2025

    Current report

Older filings on EDGAR